{"transactions":[{"id":933613,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-22T19:11:05.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"The original Form 4 filed had an incorrect number of common stock options.   This amendment presents the correct number of common stock options granted."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":91000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001133416-26-000046","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000046/form4a.xml","form_type":"4/A","original_submission_date":"2026-01-21"}},{"id":934506,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:48:29.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001133416-26-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000032/form4.xml","form_type":"4"}},{"id":934505,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:48:29.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001133416-26-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000032/form4.xml","form_type":"4"}},{"id":940298,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-13T13:40:08.000Z","date":"2026-01-05","kind":"other","planned":true,"acquired":false,"shares":56332,"price":3.88,"value":218568.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of\ndeferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing\nprice of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld from issuance to Mr. Lewis (but not sold) for federal and state withholding taxes on income."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":776260,"source":{"system":"sec-edgar","filing":"0001133416-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000010/form4.xml","form_type":"4"}},{"id":947587,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-01","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947586,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":37698,"price":3.5772,"value":134853.2856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947585,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":27731,"price":3.9069,"value":108342.2439,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":870290,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947584,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":18571,"price":4.1968,"value":77938.7728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":898021,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947583,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":916592,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":962324,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":7829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 31, 2020."}],"balance_after":32171,"derivative":{"exercise_price":2.86,"exercise_date":"2020-12-31","expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":7829},"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":962323,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":7829,"price":7.056,"value":55241.424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":962322,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":7829,"price":2.86,"value":22390.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":840421,"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":994314,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":false,"shares":6783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 14, 2018."}],"balance_after":0,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":6783},"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":994313,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":15680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 14, 2018."}],"balance_after":6783,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":15680},"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":994312,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":6783,"price":6.1511,"value":41722.9113,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":994311,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":true,"shares":6783,"price":2.39,"value":16211.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":839375,"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":994310,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":15680,"price":6.0359,"value":94642.912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":994309,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-19T21:01:27.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":15680,"price":2.39,"value":37475.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":848272,"source":{"system":"sec-edgar","filing":"0001133416-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000058/form4.xml","form_type":"4"}},{"id":1002550,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-12T21:01:37.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":1867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 14, 2018."}],"balance_after":22363,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":1867},"source":{"system":"sec-edgar","filing":"0001133416-25-000052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000052/form4.xml","form_type":"4"}},{"id":1002549,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-12T21:01:37.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":1867,"price":6.0269,"value":11252.2223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000052/form4.xml","form_type":"4"}},{"id":1002548,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-12T21:01:37.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":1867,"price":2.39,"value":4462.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":834459,"source":{"system":"sec-edgar","filing":"0001133416-25-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000052/form4.xml","form_type":"4"}},{"id":1005093,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-07T21:09:47.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 14, 2018."}],"balance_after":24230,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001133416-25-000048","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000048/form4.xml","form_type":"4"}},{"id":1005092,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-07T21:09:47.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":200,"price":6,"value":1200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000048","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000048/form4.xml","form_type":"4"}},{"id":1005091,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-07T21:09:47.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":2.39,"value":478.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":832792,"source":{"system":"sec-edgar","filing":"0001133416-25-000048","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000048/form4.xml","form_type":"4"}},{"id":1007034,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":14420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 14, 2018."}],"balance_after":24530,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":14420},"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1007033,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 14, 2018."}],"balance_after":38950,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1007032,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":14420,"price":6.07,"value":87529.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.20. This amount represents the weighted average sale price of such transactions. The reporting person\nundertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of\nthe Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1007031,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":14420,"price":2.39,"value":34463.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":847012,"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1007030,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":6.01,"value":7813.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person\nundertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of\nthe Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1007029,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:34.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":true,"shares":1300,"price":2.39,"value":3107.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":833892,"source":{"system":"sec-edgar","filing":"0001133416-25-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000044/form4.xml","form_type":"4"}},{"id":1040803,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-09-15T16:45:00.000Z","date":"2025-09-12","kind":"exercise","planned":true,"acquired":false,"shares":14000,"price":2.39,"value":33460.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 14, 2018."}],"balance_after":40250,"derivative":{"exercise_price":2.39,"exercise_date":"2018-12-14","expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001133416-25-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000038/form4.xml","form_type":"4"}},{"id":1040802,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-15T16:45:00.000Z","date":"2025-09-12","kind":"sale","planned":true,"acquired":false,"shares":14000,"price":6.3606,"value":89048.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.331 to $6.51. This amount represents the weighted average sale price of such transactions. The reporting person\nundertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of\nthe Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000038/form4.xml","form_type":"4"}},{"id":1040801,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-15T16:45:00.000Z","date":"2025-09-12","kind":"exercise","planned":true,"acquired":true,"shares":14000,"price":2.39,"value":33460.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":846592,"source":{"system":"sec-edgar","filing":"0001133416-25-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000038/form4.xml","form_type":"4"}},{"id":1223489,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-05T21:00:26.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":false,"shares":56420,"price":1.57,"value":88579.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000029/form4.xml","form_type":"4"}},{"id":1294686,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-27T21:06:25.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement."}],"balance_after":84000,"derivative":{"underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001133416-25-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000014/form4.xml","form_type":"4"}},{"id":1294685,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:06:25.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026."}],"balance_after":91000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001133416-25-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000014/form4.xml","form_type":"4"}},{"id":1322069,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-12-26T13:18:48.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001133416-24-000070","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000070/form4.xml","form_type":"4"}},{"id":1322068,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-26T13:18:48.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":56000,"price":0.8859,"value":49610.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares of common stock sold pursuant to previously disclosed 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8859."}],"balance_after":897012,"source":{"system":"sec-edgar","filing":"0001133416-24-000070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000070/form4.xml","form_type":"4"}},{"id":1322067,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-26T13:18:48.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units."}],"balance_after":953012,"source":{"system":"sec-edgar","filing":"0001133416-24-000070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000070/form4.xml","form_type":"4"}},{"id":1535573,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-25T17:27:10.000Z","date":"2024-04-24","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":3.39,"value":3390.0,"ownership":{"direct":false,"nature":"as UTMA custodian for a minor child"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents average price in multiple transactions with low of $3.30 per share and high of $3.41 per share"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents average price in multiple transactions with low of $3.30 per share and high of $3.41 per share"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001133416-24-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000040/form4.xml","form_type":"4"}},{"id":1603992,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-04T17:50:30.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":false,"shares":152584,"price":1.96,"value":299064.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":897716,"source":{"system":"sec-edgar","filing":"0001133416-24-000032","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000032/form4.xml","form_type":"4"}},{"id":1655584,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-02-07T21:48:42.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."}],"balance_after":56000,"derivative":{"underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001133416-24-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000018/form4.xml","form_type":"4"}},{"id":1655583,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-07T21:48:42.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025."}],"balance_after":91000,"derivative":{"exercise_price":1.72,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001133416-24-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000018/form4.xml","form_type":"4"}},{"id":1696809,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-02T13:07:50.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":11606,"price":1.66,"value":19265.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":1042300,"source":{"system":"sec-edgar","filing":"0001133416-24-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000002/form4.xml","form_type":"4"}},{"id":1707746,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-18T13:41:27.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":12042,"price":1.6,"value":19267.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":1030694,"source":{"system":"sec-edgar","filing":"0001133416-23-000089","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000089/form4.xml","form_type":"4"}},{"id":1725763,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-01T13:05:06.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":9880,"price":1.95,"value":19266.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":1018652,"source":{"system":"sec-edgar","filing":"0001133416-23-000087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000087/form4.xml","form_type":"4"}},{"id":1741055,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-15T22:19:22.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":10303,"price":1.87,"value":19266.61,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":1008772,"source":{"system":"sec-edgar","filing":"0001133416-23-000085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000085/form4.xml","form_type":"4"}},{"id":1753285,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-31T20:03:36.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":9444,"price":2.04,"value":19265.76,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":998469,"source":{"system":"sec-edgar","filing":"0001133416-23-000083","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000083/form4.xml","form_type":"4"}},{"id":1759964,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-16T16:36:53.000Z","date":"2023-10-13","kind":"grant","planned":false,"acquired":true,"shares":9585,"price":2.01,"value":19265.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":989025,"source":{"system":"sec-edgar","filing":"0001133416-23-000081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000081/form4.xml","form_type":"4/A","original_submission_date":"2023-10-16"}},{"id":1759963,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-16T12:09:59.000Z","date":"2023-10-13","kind":"grant","planned":false,"acquired":true,"shares":10035,"price":2.01,"value":20170.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":989025,"source":{"system":"sec-edgar","filing":"0001133416-23-000079","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000079/form4.xml","form_type":"4"}},{"id":1770670,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-02T11:43:47.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":10035,"price":1.92,"value":19267.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":979440,"source":{"system":"sec-edgar","filing":"0001133416-23-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000077/form4.xml","form_type":"4"}},{"id":1779272,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-18T13:53:44.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":10947,"price":1.76,"value":19266.72,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":969405,"source":{"system":"sec-edgar","filing":"0001133416-23-000073","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000073/form4.xml","form_type":"4"}},{"id":1791144,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-01T11:16:26.000Z","date":"2023-08-31","kind":"grant","planned":false,"acquired":true,"shares":11010,"price":1.75,"value":19267.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":958458,"source":{"system":"sec-edgar","filing":"0001133416-23-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000071/form4.xml","form_type":"4"}},{"id":1807577,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-15T20:05:05.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":12042,"price":1.6,"value":19267.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":947448,"source":{"system":"sec-edgar","filing":"0001133416-23-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000069/form4.xml","form_type":"4"}},{"id":1820593,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-31T20:14:11.000Z","date":"2023-07-31","kind":"grant","planned":false,"acquired":true,"shares":12844,"price":1.5,"value":19266.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":935406,"source":{"system":"sec-edgar","filing":"0001133416-23-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000067/form4.xml","form_type":"4"}},{"id":1828889,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-17T12:02:12.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":11820,"price":1.63,"value":19266.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":922562,"source":{"system":"sec-edgar","filing":"0001133416-23-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000063/form4.xml","form_type":"4"}},{"id":1839955,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-03T11:48:18.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":13380,"price":1.44,"value":19267.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":910.742,"source":{"system":"sec-edgar","filing":"0001133416-23-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000061/form4.xml","form_type":"4"}},{"id":1852878,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-16T11:50:44.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":13196,"price":1.46,"value":19266.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":897362,"source":{"system":"sec-edgar","filing":"0001133416-23-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000059/form4.xml","form_type":"4"}},{"id":1872360,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-01T11:53:26.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12272,"price":1.57,"value":19267.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":884166,"source":{"system":"sec-edgar","filing":"0001133416-23-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000057/form4.xml","form_type":"4"}},{"id":1891894,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-05-16T11:47:26.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":11748,"price":1.64,"value":19266.72,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":871894,"source":{"system":"sec-edgar","filing":"0001133416-23-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000055/form4.xml","form_type":"4"}},{"id":1899778,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-05-09T13:42:50.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":10947,"price":1.76,"value":19266.72,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":860146,"source":{"system":"sec-edgar","filing":"0001133416-23-000053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000053/form4.xml","form_type":"4"}},{"id":1919057,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-17T11:59:01.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":9585,"price":2.01,"value":19265.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":849199,"source":{"system":"sec-edgar","filing":"0001133416-23-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000051/form4.xml","form_type":"4"}},{"id":1932771,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-03T12:29:31.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":9175,"price":2.1,"value":19267.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":839614,"source":{"system":"sec-edgar","filing":"0001133416-23-000049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000049/form4.xml","form_type":"4"}},{"id":1950349,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-16T15:34:28.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":10140,"price":1.9,"value":19266.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":830439,"source":{"system":"sec-edgar","filing":"0001133416-23-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000047/form4.xml","form_type":"4"}},{"id":1980420,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-02T12:48:25.000Z","date":"2023-03-01","kind":"tax_withholding","acquired":false,"shares":75529,"price":2.07,"value":156345.03,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":820299,"source":{"system":"sec-edgar","filing":"0001133416-23-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000045/form4.xml","form_type":"4"}},{"id":1980419,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-02T12:48:25.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":9308,"price":2.07,"value":19267.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":895828,"source":{"system":"sec-edgar","filing":"0001133416-23-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000045/form4.xml","form_type":"4"}},{"id":2004108,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-21T13:31:14.000Z","date":"2023-02-16","kind":"purchase","acquired":true,"shares":1000,"price":1.52,"value":1520.0,"ownership":{"direct":false,"nature":"as UTMA custodian for a minor child"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act.  The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001133416-23-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000041/form4.xml","form_type":"4"}},{"id":2013934,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-15T21:06:17.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":13380,"price":1.44,"value":19267.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":886520,"source":{"system":"sec-edgar","filing":"0001133416-23-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000039/form4.xml","form_type":"4"}},{"id":2028988,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-07T12:43:16.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":143836,"price":1.43,"value":205685.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects 80% of 2022 performance bonus awarded to Mr. Lewis settled in DSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":873140,"source":{"system":"sec-edgar","filing":"0001133416-23-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000036/form4.xml","form_type":"4"}},{"id":2040556,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-31T21:03:14.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":15086,"price":1.16,"value":17499.76,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":729304,"source":{"system":"sec-edgar","filing":"0001133416-23-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000034/form4.xml","form_type":"4"}},{"id":2042450,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:36:17.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024."}],"balance_after":70000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001133416-23-000012","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000012/form4.xml","form_type":"4"}},{"id":2053943,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-17T12:51:14.000Z","date":"2023-01-13","kind":"grant","acquired":true,"shares":15351,"price":1.14,"value":17500.14,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":714218,"source":{"system":"sec-edgar","filing":"0001133416-23-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000004/form4.xml","form_type":"4"}},{"id":2072989,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-03T13:13:39.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":15487,"price":1.13,"value":17500.31,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":698867,"source":{"system":"sec-edgar","filing":"0001133416-23-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000002/form4.xml","form_type":"4"}},{"id":2085407,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-15T21:05:26.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":15086,"price":1.16,"value":17499.76,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":683380,"source":{"system":"sec-edgar","filing":"0001133416-22-000105","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000105/form4.xml","form_type":"4"}},{"id":2100291,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-01T13:26:01.000Z","date":"2022-11-30","kind":"grant","acquired":true,"shares":13780,"price":1.27,"value":17500.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":668294,"source":{"system":"sec-edgar","filing":"0001133416-22-000103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000103/form4.xml","form_type":"4"}},{"id":2116546,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-15T21:06:36.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":14113,"price":1.24,"value":17500.12,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":654514,"source":{"system":"sec-edgar","filing":"0001133416-22-000099","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000099/form4.xml","form_type":"4"}},{"id":2128699,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-01T13:35:01.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":12681,"price":1.38,"value":17499.78,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":640401,"source":{"system":"sec-edgar","filing":"0001133416-22-000097","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000097/form4.xml","form_type":"4"}},{"id":2136458,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-17T11:52:58.000Z","date":"2022-10-14","kind":"grant","acquired":true,"shares":10802,"price":1.62,"value":17499.24,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":627720,"source":{"system":"sec-edgar","filing":"0001133416-22-000091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000091/form4.xml","form_type":"4"}},{"id":2147724,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-03T15:45:00.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":10736,"price":1.63,"value":17499.68,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":616918,"source":{"system":"sec-edgar","filing":"0001133416-22-000089","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000089/form4.xml","form_type":"4/A","original_submission_date":"2022-10-03"}},{"id":2147723,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-03T13:22:25.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":10736,"price":1.79,"value":19217.44,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":616918,"source":{"system":"sec-edgar","filing":"0001133416-22-000087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000087/form4.xml","form_type":"4"}},{"id":2158646,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-15T20:22:20.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":9777,"price":1.79,"value":17500.83,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":606182,"source":{"system":"sec-edgar","filing":"0001133416-22-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000084/form4.xml","form_type":"4"}},{"id":2169192,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-01T13:13:38.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":9211,"price":1.9,"value":17500.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":596405,"source":{"system":"sec-edgar","filing":"0001133416-22-000082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000082/form4.xml","form_type":"4"}},{"id":2185839,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-15T21:46:56.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":8028,"price":2.18,"value":17501.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":587194,"source":{"system":"sec-edgar","filing":"0001133416-22-000080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000080/form4.xml","form_type":"4"}},{"id":2199237,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-01T16:40:29.000Z","date":"2022-07-29","kind":"grant","acquired":true,"shares":7743,"price":2.26,"value":17499.18,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"shares","element":"transactionShares","label":"F3","text":"This Form 4A is filed to correct the number of shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":552139,"source":{"system":"sec-edgar","filing":"0001133416-22-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000077/form4.xml","form_type":"4/A","original_submission_date":"2022-08-01"}},{"id":2199238,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-01T11:07:32.000Z","date":"2022-07-29","kind":"grant","acquired":true,"shares":10606,"price":2.26,"value":23969.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":552139,"source":{"system":"sec-edgar","filing":"0001133416-22-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000075/form4.xml","form_type":"4"}},{"id":2206387,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-18T11:58:24.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":10606,"price":1.65,"value":17499.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":544396,"source":{"system":"sec-edgar","filing":"0001133416-22-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000071/form4.xml","form_type":"4"}},{"id":2217561,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-01T13:18:20.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":13359,"price":1.31,"value":17500.29,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":533790,"source":{"system":"sec-edgar","filing":"0001133416-22-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000069/form4.xml","form_type":"4"}},{"id":2230346,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-16T11:25:51.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":13780,"price":1.29,"value":17776.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":520431,"source":{"system":"sec-edgar","filing":"0001133416-22-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000067/form4.xml","form_type":"4"}},{"id":2249814,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-01T13:26:23.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":13566,"price":1.29,"value":17500.14,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":506651,"source":{"system":"sec-edgar","filing":"0001133416-22-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000065/form4.xml","form_type":"4"}},{"id":2270687,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-16T11:37:06.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":12868,"price":1.36,"value":17500.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":493085,"source":{"system":"sec-edgar","filing":"0001133416-22-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000061/form4.xml","form_type":"4"}},{"id":2286719,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-02T11:13:15.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":11290,"price":1.55,"value":17499.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":480217,"source":{"system":"sec-edgar","filing":"0001133416-22-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000059/form4.xml","form_type":"4"}},{"id":2295822,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-18T11:38:04.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":10057,"price":1.74,"value":17499.18,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":468927,"source":{"system":"sec-edgar","filing":"0001133416-22-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000055/form4.xml","form_type":"4"}},{"id":2313299,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-31T20:07:07.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":10870,"price":1.61,"value":17500.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":458870,"source":{"system":"sec-edgar","filing":"0001133416-22-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000051/form4.xml","form_type":"4"}},{"id":2331085,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-16T15:42:07.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":10057,"price":1.74,"value":17499.18,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":448000,"source":{"system":"sec-edgar","filing":"0001133416-22-000049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000049/form4.xml","form_type":"4"}},{"id":2366056,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-01T13:04:05.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":9358,"price":1.87,"value":17499.46,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":437.943,"source":{"system":"sec-edgar","filing":"0001133416-22-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000047/form4.xml","form_type":"4"}},{"id":2394882,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-15T21:08:28.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":8454,"price":2.07,"value":17499.78,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":428585,"source":{"system":"sec-edgar","filing":"0001133416-22-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000045/form4.xml","form_type":"4"}},{"id":2419554,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-01T15:11:13.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":112263,"price":1.93,"value":216667.59,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":420131,"source":{"system":"sec-edgar","filing":"0001133416-22-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000041/form4.xml","form_type":"4"}},{"id":2426927,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:15:20.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023."}],"balance_after":70000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001133416-22-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000014/form4.xml","form_type":"4"}},{"id":2434025,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-18T13:07:12.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":8251,"price":2.02,"value":16667.02,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":307868,"source":{"system":"sec-edgar","filing":"0001133416-22-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000004/form4.xml","form_type":"4"}},{"id":2454686,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-03T12:51:41.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":8052,"price":2.07,"value":16667.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be\npaid in the form of deferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis\npursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1,\n2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":299617,"source":{"system":"sec-edgar","filing":"0001133416-22-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000002/form4.xml","form_type":"4"}}],"next_cursor":"2022-01-03T12:51:41.000000Z,2454686"}